Statins × all-cause mortality

SynthesisCirculation2010

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.

Samia Mora et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 6,801 people · 2010

Randomised comparison

Reduced deaths

−37%−51% to −18%

Bigger than 8 in 10 for all-cause mortality

As reported

RR 0.63, 95% CI 0.49–0.82 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on deaths

−22%−47% to +15%

Bigger than 7 in 10 for all-cause mortality

As reported

RR 0.78, 95% CI 0.53–1.15 · the paper's word: All-cause mortality

Two numbers in the abstract

the abstract, start to end

with statins by a third (relative risk, 0.63; 95% confidence interval, 0.49 to 0.82; P<0.001; P for heterogeneity=0.56) with a smaller nonsignificant effect on total mortality (relative risk, 0.78; 95% confidence interval, 0.53

← favours treatmentfavours comparator →
could be chance
All-cause mortality
RR 0.630.49–0.82
All-cause mortality
RR 0.780.53–1.15
StatinsAll-cause mortality

Statins × all-cause mortalityhelps?mixed

unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

111 papers cite itlatest 60 shown

2010
2011
2012
2013
2014
2016
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 20176986